Tesevatinib (EXEL-7647; XL-647; KD-019) is a novel, oral and potent receptor tyrosine kinase (RTK) inhibitor that targets multi-kinases including EGFR, ErbB2, KDR, Flt4 and EphB4 with IC50s of 0.3, 16, 1.5, 8.7, and 1.4 nM. It exhibits anticancer activity by inhibiting tumor growth and angiogenesis, and tumor regression.

纯度：≥98%

CAS：781613-23-8